- +121.7% price growth over the last year
- Lower volatility than the market (beta 0.55)
- Highly efficient cash conversion (104% FCF/OCF ratio)
SAB Biotherapeutics, Inc. stock upgraded from Hold/Accumulate to Buy Candidate after Wednesday trading session
(Updated on Jul 01, 2026)
The SAB Biotherapeutics, Inc. stock price fell by -0.513% on the last day (Wednesday, 1st Jul 2026) from $3.90 to $3.88. During the last trading day the stock fluctuated 3.15% from a day low at $3.81 to a day high of $3.93. The price has fallen in 5 of the last 10 days but is still up by 6.01% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -106 thousand shares and in total, 302 thousand shares were bought and sold for approximately $1.17 million.
The stock lies the upper part of a wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $3.98 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -3.05% during the next 3 months and, with a 90% probability hold a price between $3.18 and $3.86 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
SABS Signals & Forecast
The SAB Biotherapeutics, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $3.87 and $3.67. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, June 18, 2026, and so far it has fallen -3.00%. Further fall is indicated until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Support, Risk & Stop-loss for SAB Biotherapeutics, Inc. stock
SAB Biotherapeutics, Inc. finds support from accumulated volume at $3.80 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.120 between high and low, or 3.15%. For the last week the stock has had daily average volatility of 4.43%.
Our recommended stop-loss: $3.71 (-4.38%) (This stock has high daily movements and this gives high risk. There is a sell signal from a pivot top found 8 days ago.)
Trading Expectations (SABS) For The Upcoming Trading Day Of Thursday 2nd
For the upcoming trading day on Thursday, 2nd we expect SAB Biotherapeutics, Inc. to open at $3.87, and during the day (based on 14 day Average True Range), to move between $3.77 and $3.99, which gives a possible trading interval of +/-$0.222 (+/-5.90%) up or down from last closing price. If SAB Biotherapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 5.90% move between the lowest and the highest trading price during the day.
Since the stock is closer to the resistance from accumulated volume at $3.90 (0.52%) than the support at $3.80 (2.06%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.
Is SAB Biotherapeutics, Inc. stock A Buy?
Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold to a Buy candidate.
Current score:
1.599
Buy Candidate
Upgraded
Predicted Fair Opening Price
Predicted fair opening price on July 2, 2026 - $3.87 ( 0.172%).
Want to trade but not sure how?
Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* 
*Your capital is at risk
SABS Performance
Trading levels for SABS
Fibonacci Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 3.99 | 2.92% |
| R2 | 3.95 | 1.74% |
| R1 | 3.92 | 1.01% |
| Price | 3.88 | |
| S1 | 3.83 | -1.35% |
| S2 | 3.80 | -2.08% |
| S3 | 3.75 | -3.26% |
Accumulated Volume Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 4.11 | 5.93% |
| R2 | 4.09 | 5.41% |
| R1 | 3.90 | 0.515% |
| Price | 3.88 | |
| S1 | 3.80 | -2.06% |
| S2 | 3.72 | -4.12% |
| S3 | 3.66 | -5.67% |
FAQ
Click here for our free guide on how to buy SAB Biotherapeutics, Inc. Stock.
Buy SABS